Literature DB >> 9811348

Endogenous proteolytic cleavage of normal and disease-associated isoforms of the human prion protein in neural and non-neural tissues.

A Jiménez-Huete1, P M Lievens, R Vidal, P Piccardo, B Ghetti, F Tagliavini, B Frangione, F Prelli.   

Abstract

We have investigated the proteolytic cleavage of the cellular (PrPC) and pathological (PrPSc) isoforms of the human prion protein (PrP) in normal and prion-affected brains and in tonsils and platelets from neurologically intact individuals. The various PrP species were resolved after deglycosylation according to their electrophoretic mobility, immunoreactivity, Sarkosyl solubility, and, as a novel approach, resistance to endogenous proteases. First, our data show that PrPC proteolysis in brain originates amino-truncated peptides of 21 to 22 and 18 (C1) kd that are similar in different regions and are not modified by the PrP codon 129 genotype, a polymorphism that affects the expression of prion disorders. Second, this proteolytic cleavage of PrPC in brain is blocked by inhibitors of metalloproteases. Third, differences in PrPC proteolysis, and probably in Asn glycosylation and glycosylphosphatidylinositol anchor composition, exist between neural and non-neural tissues. Fourth, protease-resistant PrPSc cores in sporadic Creutzfeldt-Jakob disease (CJD) and Gerstmann-Sträussler-Scheinker F198S disease brains all have an intact C1 cleavage site (Met111-His112), which precludes disruption of a domain associated with toxicity and fibrillogenesis. Fifth, the profile of endogenous proteolytic PrPSc peptides is characteristic of each disorder studied, thus permitting the molecular classification of these prion diseases without the use of proteinase K and even a recognition of PrPSc heterogeneity within type 2 CJD patients having different codon 129 genotype and neuropathological phenotype. This does not exclude the role of additional factors in phenotypic expression; in particular, differences in glycosylation that may be especially relevant in the new variant CJD. Proteolytic processing of PrP may play an important role in the neurotropism and phenotypic expression of prion diseases, but it does not appear to participate in disease susceptibility.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9811348      PMCID: PMC1853409          DOI: 10.1016/S0002-9440(10)65744-6

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  60 in total

1.  A conformational transition at the N terminus of the prion protein features in formation of the scrapie isoform.

Authors:  D Peretz; R A Williamson; Y Matsunaga; H Serban; C Pinilla; R B Bastidas; R Rozenshteyn; T L James; R A Houghten; F E Cohen; S B Prusiner; D R Burton
Journal:  J Mol Biol       Date:  1997-10-31       Impact factor: 5.469

2.  Asparagine-linked glycosylation of the scrapie and cellular prion proteins.

Authors:  T Haraguchi; S Fisher; S Olofsson; T Endo; D Groth; A Tarentino; D R Borchelt; D Teplow; L Hood; A Burlingame
Journal:  Arch Biochem Biophys       Date:  1989-10       Impact factor: 4.013

3.  Recombinant full-length murine prion protein, mPrP(23-231): purification and spectroscopic characterization.

Authors:  S Hornemann; C Korth; B Oesch; R Riek; G Wider; K Wüthrich; R Glockshuber
Journal:  FEBS Lett       Date:  1997-08-18       Impact factor: 4.124

4.  Detection of distinct isoform patterns of the beta-amyloid precursor protein in human platelets and lymphocytes.

Authors:  M G Schlossmacher; B L Ostaszewski; L I Hecker; A Celi; C Haass; D Chin; I Lieberburg; B C Furie; B Furie; D J Selkoe
Journal:  Neurobiol Aging       Date:  1992 May-Jun       Impact factor: 4.673

Review 5.  Molecular biology and pathogenesis of prion diseases.

Authors:  S B Prusiner
Journal:  Trends Biochem Sci       Date:  1996-12       Impact factor: 13.807

6.  Metal-dependent alpha-helix formation promoted by the glycine-rich octapeptide region of prion protein.

Authors:  T Miura; A Hori-i; H Takeuchi
Journal:  FEBS Lett       Date:  1996-11-04       Impact factor: 4.124

7.  Truncated forms of the human prion protein in normal brain and in prion diseases.

Authors:  S G Chen; D B Teplow; P Parchi; J K Teller; P Gambetti; L Autilio-Gambetti
Journal:  J Biol Chem       Date:  1995-08-11       Impact factor: 5.157

8.  The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part X. Neuropathology confirmation of the clinical diagnosis of Alzheimer's disease.

Authors:  M Gearing; S S Mirra; J C Hedreen; S M Sumi; L A Hansen; A Heyman
Journal:  Neurology       Date:  1995-03       Impact factor: 9.910

9.  Fatal familial insomnia and familial Creutzfeldt-Jakob disease: disease phenotype determined by a DNA polymorphism.

Authors:  L G Goldfarb; R B Petersen; M Tabaton; P Brown; A C LeBlanc; P Montagna; P Cortelli; J Julien; C Vital; W W Pendelbury
Journal:  Science       Date:  1992-10-30       Impact factor: 47.728

10.  Transgenetic studies implicate interactions between homologous PrP isoforms in scrapie prion replication.

Authors:  S B Prusiner; M Scott; D Foster; K M Pan; D Groth; C Mirenda; M Torchia; S L Yang; D Serban; G A Carlson
Journal:  Cell       Date:  1990-11-16       Impact factor: 41.582

View more
  52 in total

1.  Prion infection impairs the cellular response to oxidative stress.

Authors:  O Milhavet; H E McMahon; W Rachidi; N Nishida; S Katamine; A Mangé; M Arlotto; D Casanova; J Riondel; A Favier; S Lehmann
Journal:  Proc Natl Acad Sci U S A       Date:  2000-12-05       Impact factor: 11.205

2.  Sphingosine kinase-dependent migration of immature dendritic cells in response to neurotoxic prion protein fragment.

Authors:  Nicole C Kaneider; Arthur Kaser; Stefan Dunzendorfer; Herbert Tilg; Christian J Wiedermann
Journal:  J Virol       Date:  2003-05       Impact factor: 5.103

3.  Proteolytic processing and glycosylation influence formation of porcine prion protein complexes.

Authors:  Krzysztof Nieznanski; Marcin Rutkowski; Magdalena Dominik; Dariusz Stepkowski
Journal:  Biochem J       Date:  2005-04-01       Impact factor: 3.857

4.  Molecular profiling of ovine prion diseases by using thermolysin-resistant PrPSc and endogenous C2 PrP fragments.

Authors:  Jonathan P Owen; Helen C Rees; Ben C Maddison; Linda A Terry; Leigh Thorne; Roy Jackman; Garry C Whitelam; Kevin C Gough
Journal:  J Virol       Date:  2007-07-25       Impact factor: 5.103

5.  The alpha-secretase-derived N-terminal product of cellular prion, N1, displays neuroprotective function in vitro and in vivo.

Authors:  Marie-Victoire Guillot-Sestier; Claire Sunyach; Charlotte Druon; Sabine Scarzello; Frédéric Checler
Journal:  J Biol Chem       Date:  2009-12-18       Impact factor: 5.157

6.  Clearance and prevention of prion infection in cell culture by anti-PrP antibodies.

Authors:  Joanna Pankiewicz; Frances Prelli; Man-Sun Sy; Richard J Kascsak; Regina B Kascsak; Daryl S Spinner; Richard I Carp; Harry C Meeker; Marcin Sadowski; Thomas Wisniewski
Journal:  Eur J Neurosci       Date:  2006-05       Impact factor: 3.386

7.  Apparent reduction of ADAM10 in scrapie-infected cultured cells and in the brains of scrapie-infected rodents.

Authors:  Cao Chen; Yan Lv; Bao-Yun Zhang; Jin Zhang; Qi Shi; Jing Wang; Chan Tian; Chen Gao; Kang Xiao; Ke Ren; Wei Zhou; Xiao-Ping Dong
Journal:  Mol Neurobiol       Date:  2014-04-26       Impact factor: 5.590

8.  Separate mechanisms act concurrently to shed and release the prion protein from the cell.

Authors:  Lotta Wik; Mikael Klingeborn; Hanna Willander; Tommy Linne
Journal:  Prion       Date:  2012-10-23       Impact factor: 3.931

9.  Scrapie protein degradation by cysteine proteases in CD11c+ dendritic cells and GT1-1 neuronal cells.

Authors:  Katarina M Luhr; Elin K Nordström; Peter Löw; Hans-Gustaf Ljunggren; Albert Taraboulos; Krister Kristensson
Journal:  J Virol       Date:  2004-05       Impact factor: 5.103

10.  Unexpected tolerance of alpha-cleavage of the prion protein to sequence variations.

Authors:  José B Oliveira-Martins; Sei-ichi Yusa; Anna Maria Calella; Claire Bridel; Frank Baumann; Paolo Dametto; Adriano Aguzzi
Journal:  PLoS One       Date:  2010-02-08       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.